This study provides key strategies for antibody drug development and vaccine evaluation, revealing that sequential supplementation of secondary signals can overcome immune deficiencies in humanized mice, directly inspiring the optimization of related experimental designs.
Literature Overview
The article "Optimization of B Cell Responses in Human Immune System Mice Through Organoid Based Screening," published in Advanced Science, systematically explores the use of a splenic organoid platform to screen for key signaling molecules. This approach addresses the issues of weak B cell responses to exogenous antigens, low antibody titers, and insufficient effector subset differentiation in Human Immune System (HIS) mice.Background Knowledge
Humanized mice are critical tools for studying human immune diseases and developing antibody drugs; however, their B cell functions exhibit significant defects. The primary challenge lies in the lack of secondary signals provided by T cells, preventing effective B cell proliferation and class switching. Currently, delivering key signaling molecules such as CD40L and IL-4 in vivo faces challenges related to non-specific activation and toxicity. This study focuses on establishing an in vitro organoid screening system to precisely identify missing signal combinations and explore strategies for their sequential delivery in vivo. This approach aims to bypass T cell functional defects and directly activate antigen-sensitized B cells.
Research Methods and Core Experiments
The authors first established an organoid culture system derived from the spleens of HIS mice. Using this platform, they performed high-throughput screening of various cytokine combinations, including IL-4, IL-10, IL-21, and CD40L. The experiments revealed that the combined use of CD40L with IL-4, IL-10, and IL-21 significantly drove B cell proliferation and plasma cell differentiation. Further screening identified that the synergistic action of TNF-α and CpG promoted IgG class switching. Subsequently, the research team validated the "antigen sensitization-secondary signal supplementation" strategy in vivo by administering recombinant proteins via intravenous injection rather than plasmids, thereby avoiding non-specific inflammation and weight loss.Key Conclusions and Perspectives
Research Significance and Prospects
This discovery has profound implications for antibody drug development, offering a universal strategy to enhance immune responses in HIS mice without complex genetic engineering. By optimizing the timing and combination of signal delivery, researchers can more effectively screen for high-affinity fully human antibodies in vivo, significantly shortening the drug discovery cycle. Furthermore, this strategy provides a new optimization scheme for in vivo models in vaccine immunological evaluation, aiding in more accurate predictions of the immunogenicity of candidate vaccines in humans.
Conclusion
By constructing a splenic organoid screening platform, this study successfully resolved the challenge of weak B cell immune responses in humanized mice. Through the precise identification and sequential delivery of key signals such as CD40L, IL-4, IL-21, and TNF-α, the research team not only restored B cell proliferation and differentiation capabilities but also achieved efficient IgG class switching. This strategy provides a powerful tool for antibody drug development and infectious disease vaccine research, making it possible to obtain clinically relevant neutralizing antibodies using HIS mice. From laboratory screening to in vivo validation, this work demonstrates the central role of optimizing the immune microenvironment in enhancing model predictive value, laying a solid experimental foundation for future immunotherapy research in autoimmune and infectious diseases.
